ValueQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMSelling/general/admin expenses2.87 M2.68 M1.64 M4.39 M2.16 M21.05 M29.24 MResearch & development—————5.64 M—Operating income-13.33 M4.82 M-5.88 M-8.61 M-7.34 M-5.99 M-27.83 MNon-Operating Income, Total0————-1.94 M—Interest expense, net of interest capitalized—————2.91 M—Non-Operating Income, excl. Interest Expenses0————-5.13 M—Unusual income/expense—————290 K—Pretax income-19.81 M4.82 M-5.88 M-8.61 M-250.64 M-7.93 M-273.06 MEquity in earnings0——————Taxes-87 K03 0000003 000Non-controlling/minority interest———————After tax other income/expense0——————Net income before discontinued operations-19.73 M-54.15 M-26.64 M-146.34 M-23.5 M-7.93 M-204.42 MDiscontinued operations0———0——Net income-19.73 M-54.15 M-26.64 M-146.34 M-23.5 M-7.93 M-204.42 MDilution adjustment———————Preferred dividends———————Diluted net income available to common stockholders-19.73 M-54.15 M-26.64 M-325.34 M-23.5 M-7.93 M-383.42 MBasic earnings per share (Basic EPS)-0.05-0.18-0.09-1.06-0.04-0.02-1.21Diluted earnings per share (Diluted EPS)-0.05-0.18-0.09-1.06-0.04-0.02-1.21Average basic shares outstanding267.73 M293.88 M296.43 M307.17 M312.98 M354.29 M—Diluted shares outstanding267.73 M293.88 M296.43 M307.17 M312.98 M354.29 M—EBITDA-12.67 M————-4.89 M—EBIT-13.33 M————-5.99 M—Cost of revenue———————Other cost of goods sold———————Depreciation & amortization (cash flow)661 K629 K630 K803 K1.14 M1.1 M3.67 M
Precigen, Inc. - Common Stock
Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari.
Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.